An Overview on the Potential Roles of EGCG in the Treatment of COVID-19 Infection

Drug Des Devel Ther. 2021 Oct 28:15:4447-4454. doi: 10.2147/DDDT.S314666. eCollection 2021.

Abstract

Coronavirus disease-19 (COVID-19) pandemic is currently ongoing worldwide and causes a lot of deaths in many countries. Although different vaccines for the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection have been developed and are now available, there are no effective antiviral drugs to treat the disease, except for Remdesivir authorized by the US FDA to counteract the emergency. Thus, it can be useful to find alternative therapies based on the employment of natural compounds, with antiviral features, to circumvent SARS-CoV-2 infection. Pre-clinical studies highlighted the antiviral activities of epigallocatechin-3-gallate (EGCG), a catechin primarily found in green tea, against various viruses, including SARS-CoV-2. In this review, we summarize this experimental evidence and highlight the potential use of EGCG as an alternative therapeutic choice for the treatment of SARS-CoV-2 infection.

Keywords: COVID-19; EGCG; SARS-CoV-2; antiviral properties; tea polyphenols.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacology*
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Catechin / administration & dosage
  • Catechin / analogs & derivatives*
  • Catechin / pharmacology
  • Humans
  • Tea / chemistry

Substances

  • Antiviral Agents
  • Tea
  • Catechin
  • epigallocatechin gallate